⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EYPT News
EyePoint Pharmaceuticals, Inc. Common Stock
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
EYPT
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
globenewswire.com
EYPT
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
EYPT
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
EYPT
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
globenewswire.com
EYPT
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
EYPT
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
globenewswire.com
EYPT
EyePoint Announces Participation at Upcoming Investor Conferences
globenewswire.com
EYPT
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
globenewswire.com
EYPT
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
EYPT